|
CLCN4 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.43030001573419E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.3742000304926E-09 |
| Normal-vs-Stage2 |
3.562200E-01 |
| Normal-vs-Stage3 |
1.07030000418007E-08 |
| Normal-vs-Stage4 |
2.17180051720334E-10 |
| Stage1-vs-Stage2 |
1.515290E-03 |
| Stage1-vs-Stage3 |
1.705170E-01 |
| Stage1-vs-Stage4 |
1.410060E-02 |
| Stage2-vs-Stage3 |
7.81050000000505E-05 |
| Stage2-vs-Stage4 |
2.32379999999255E-05 |
| Stage3-vs-Stage4 |
3.201800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
8.50097769955482E-13 |
| Normal-vs-AfricanAmerican |
5.823900E-04 |
| Normal-vs-Asian |
1.3588999999703E-06 |
| Caucasian-vs-AfricanAmerican |
3.351000E-01 |
| Caucasian-vs-Asian |
5.024600E-01 |
| AfricanAmerican-vs-Asian |
6.789800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.66550020838952E-10 |
| Normal-vs-Female |
9.73360000378065E-08 |
| Male-vs-Female |
1.121990E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
5.01209995729113E-09 |
| Normal-vs-Age(41-60Yrs) |
1.13460000283894E-08 |
| Normal-vs-Age(61-80Yrs) |
4.32230000000366E-05 |
| Normal-vs-Age(81-100Yrs) |
4.044800E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.156800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.585800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.225200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.788200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.262600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
1.798800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.231350E-04 |
| Classical-VS-Follicular |
8.62690000547062E-08 |
| Classical-VS-Other |
8.385800E-01 |
| Classical-VS-Normal |
1.95021776505655E-12 |
| Tall-VS-Follicular |
6.79400979919365E-12 |
| Tall-VS-Other |
1.108830E-01 |
| Tall-VS-Normal |
9.15933995315754E-14 |
| Follicular-VS-Other |
7.244600E-03 |
| Follicular-VS-Normal |
4.684200E-01 |
| Other-VS-Normal |
5.103200E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.181300E-04 |
| Normal-vs-N1 |
8.26450019530967E-13 |
| N0-vs-N1 |
1.33989999995254E-06 |
|
|
